samedan logo
home > pmps > winter 2021 > spotlight - dupont - dosage forms and release technologies
Pharmaceutical Manufacturing and Packing Sourcer

Spotlight - DuPont - Dosage Forms and Release Technologies

PMPS: METHOCEL™ DC2 HPMC offers fewer production steps and less waste, how can this, and similar new technologies, help the industry from drug creation to delivery?

Rina Chokshi: The main advantages of METHOCEL™ DC2 HPMC are its ease of use and simplified application during direct compression manufacturing (1). It improves content uniformity of the final dosage form, resulting in lower cost of production and more consistent product performance for patients.

METHOCEL™ DC2 HPMC also has implications for those wishing to adopt continuous manufacturing. Its improved flow properties are essential to maintaining performance and high throughput. METHOCEL™ DC2 HPMC’s particle morphology is specifically designed to offer better flow, as the particles are less fibrous, more spherical, and homogenous in shape and physical properties. Because of this, manufacturers can avoid more expensive and complex granulation processes.

Our Alubra® sodium stearyl fumarate boasts benefits for continuous manufacturing, too (2). It helps manufacturers achieve desired tablet hardness, while avoiding over-lubrication since it can be integrated earlier in the process than alternative products, thus circumventing lubrication issues.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Rina Chokshi, Global Commercial Manager at DuPont Pharma Solutions
Print this page
Send to a friend
Privacy statement
News and Press Releases

DFE Pharma opens its new Center of Excellence in India to provide fast-track formulation services

The new ‘Closer to the Formulator’ (C2F) center offers DFE Pharma’s excipient expertise to help pharmaceutical companies achieve ‘first-time right’ formulations.
More info >>

White Papers

Pandemic respiratory vaccine clinical trials: a departure from business as usual

ICON plc

Around the world, the “V” words are on everyone’s lips: Virus and Vaccines. In response to the urgent need for a vaccine for COVID-19, researchers are, at time of publication, running 500+ clinical trials (and counting) on a number of antivirals, antibodies and vaccines. Promising possibilities range from novel new drugs/vaccines, repurposing treatments currently indicated for HIV, Ebola and malaria, to monoclonal antibodies and immune serum.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement